de Bastos Daniel Rodrigues, Longatto-Filho Adhemar, Conceição Mércia Patrícia Ferreira, Termini Lara
Department of Radiology and Oncology São Paulo University, Institute of Cancer of São Paulo Faculty of Medicine, São Paulo, Brazil.
Medical Laboratory of Medical Investigation (LIM) 14, Department of Pathology, São Paulo University Faculty of Medicine, São Paulo, Brazil.
Eur J Breast Health. 2024 Jul 1;20(3):185-193. doi: 10.4274/ejbh.galenos.2024.2024-3-6.
Breast cancer is classified based on hormone receptor status and human epidermal growth factor receptor 2 (HER2) expression, including luminal, HER2+, or triple-negative (TNBC). The absence of a therapeutic target in TNBC and the resistance to treatment associated with other subtypes means that research for new biomarkers remains important. In this context, superoxide dismutase 2 (SOD2) has emerged as a potential therapeutic target due to its clinicopathological associations and its ability to predict responses in human tumors. To analyze SOD2 staining in samples obtained from individuals with breast cancer and explore its transcriptional pattern across tumor subtypes.
SOD2 staining was assessed using the immunohistochemistry (IHC) in 80 samples from breast cancer patients. To analyze the expression profile at the transcriptional level, international databases such as cBioPortal (1,980 patients) and PrognoScan were accessed.
Significant differences were observed between SOD2 expression analyzed by IHC, and estrogen ( = 0.0008) and progesterone ( = 0.0003) receptors, as well as tumor subtypes (<0.0001). These differences were found in conjunction with other associations, including clinical and pathological data, such as tumor stage ( = 0.0129), tumor size ( = 0.0296), and node metastasis ( = 0.0486). Moreover, elevated SOD2 expression correlated with an unfavorable prognosis. The analysis revealed a similar pattern, despite operating at the transcriptional level. Moreover, notable correlations were identified between elevated SOD2 expression and worse survival.
These results highlight the importance of SOD2 in breast cancer, particularly in aggressive subtypes. Increased SOD2 staining correlates with poorer outcomes, suggesting it as a potential therapeutic target.
乳腺癌根据激素受体状态和人表皮生长因子受体2（HER2）表达进行分类，包括管腔型、HER2阳性型或三阴性（TNBC）。TNBC缺乏治疗靶点以及与其他亚型相关的治疗耐药性意味着寻找新的生物标志物的研究仍然很重要。在这种背景下，超氧化物歧化酶2（SOD2）因其临床病理相关性及其预测人类肿瘤反应的能力而成为一个潜在的治疗靶点。分析从乳腺癌患者获取的样本中SOD2染色情况，并探讨其在不同肿瘤亚型中的转录模式。
使用免疫组织化学（IHC）对80例乳腺癌患者的样本进行SOD2染色评估。为了在转录水平分析表达谱，访问了cBioPortal（1980例患者）和PrognoScan等国际数据库。
通过IHC分析的SOD2表达与雌激素（P = 0.0008）、孕激素（P = 0.0003）受体以及肿瘤亚型（P<0.0001）之间存在显著差异。这些差异与其他关联因素相关，包括临床和病理数据，如肿瘤分期（P = 0.0129）、肿瘤大小（P = 0.0296）和淋巴结转移（P = 0.0486）。此外，SOD2表达升高与不良预后相关。转录水平分析揭示了类似的模式。此外，还发现SOD2表达升高与较差的生存率之间存在显著相关性。
这些结果突出了SOD2在乳腺癌中的重要性，特别是在侵袭性亚型中。SOD2染色增加与较差的预后相关，表明它是一个潜在的治疗靶点。
